Phenotypes Associated with This Genotype

Genotype
MGI:3814543

• Allelic Composition: Runx1^tm3Dow/Runx1⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased tumor-free survival time ( J:77129 )

• mice treated with pI:pC and ENU die rapidly between 2 and 10 months coincident with tumor presentation

neoplasm

increased tumor incidence ( J:77129 )

• 47% of 5-10 week old mice treated with pI:pC then treated with ENU develop hematopoietic neoplasms 2-10 months after treatment

increased T cell derived lymphoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop thymic derived T cell lymphoblastic lymphomas (17%)

increased acute promyelocytic leukemia incidence ( J:77129 )

• some pI:pC and ENU treated mice develop granulocytic sarcoma/acute myeloid leukemia (30%)

increased sarcoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop granulocytic sarcoma/acute myeloid leukemia (30%); these are solid masses of proliferating myeloblasts which form in retroperitoneum, soft tissue, or in bones of sternum, cranium, or extremities adjacent to soft tissue

• tumor cells disseminate widely, with clusters of cells found in spleen, liver, kidney and lymph nodes

• in some mice, increased myeloblasts are observed in bone marrow, as well as markedly increased white blood cell counts with identifiable circulating leukemic blasts

• tumors are transplantable

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop thymic derived T cell lymphoblastic lymphomas (17%)

hematopoietic system

hematopoietic system phenotype ( J:77129 )

N • mimimal abnormalities in hematopoiesis are observed in mutants expressing the Runx1 knock-in allele after pI:pC treatment, although a slight increase in granulocyte-monocyte, mixed and total colonies, as well as in day 12 CFUs in bone marrow, is seen

N • no leukemia develops during the first 11months of life of treated mutants

abnormal hematopoietic system morphology/development ( J:77129 )

• 2 mice develop hematopoietic neoplasms by 1 year of age (1 T cell lymphoma, 1 undifferentiated lymphoma)

increased T cell derived lymphoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop thymic derived T cell lymphoblastic lymphomas (17%)

cellular

abnormal cell physiology ( J:77129 )

• bone marrow cells isolated from mice treated with pI:pC show enhanced replating efficiency in culture; cells are able to form myeloid colonies long after wild-type cells have stopped growing

immune system

increased T cell derived lymphoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop thymic derived T cell lymphoblastic lymphomas (17%)